Skip to content

Understanding the role of inflammation In Congenital Ichthyosis

Understanding the role of Th17 Pathway In The Pathogenesis of Congenital Non-Syndromic Ichthyosis - None

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/03/018283
Enrollment
80
Registered
2019-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L86- Keratoderma in diseases classifiedelsewhere

Interventions

Sponsors

Indian Association of Dermatologists Venereologists and Leprologists
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Non syndromic congenital ichthyosis patients regardless of age and sex. 2. Patients who can give valid consent

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Ichthyosis vulgaris 2. Those who cannot provide consent for the study

Design outcomes

Primary

MeasureTime frame
1.Mean difference in serum IL-17A and levels between patients and controls 2.Mean difference in Th17 cell levels 3.Mean difference in mRNA expression levels of IL-17 gene in peripheral blood mononuclear cells 4.Mean difference in tissue expression of IL-17 gene in skin biopsy samplesTimepoint: 1.Mean difference in serum IL-17A and levels between patients and controls - 2 years 2.Mean difference in Th17 cell levels - 2 years 3.Mean difference in mRNA expression levels of IL-17 gene in peripheral blood mononuclear cells- 2 years 4.Mean difference in tissue expression of IL-17 gene in skin biopsy samples - 2 years

Secondary

MeasureTime frame
Secondary objective 1. Mean difference in serum IL-22 levels, a downstream IL between patients and controls 2. Mean difference in mRNA expression levels of IL-22 gene between patients and controls in peripheral blood mononuclear cells 3. Mean difference in tissue mRNA expression levels of IL-22 gene between patients and controls in skin biopsy samples Timepoint: AT THE END OF STUDY PERIOD

Countries

India

Contacts

Public ContactRahul Mahajan

PGIMER Chandigarh

drrahulpgi@yahoo.com7087009079

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026